Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report released on Sunday morning. The firm issued a hold rating on the medical research company’s stock.

A number of other brokerages also recently commented on CTSO. D. Boral Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a research report on Friday. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a report on Monday, November 11th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Up 1.8 %

CTSO stock opened at $0.94 on Friday. The firm has a market cap of $51.21 million, a PE ratio of -2.60 and a beta of 0.58. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $1.59. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The firm has a 50 day simple moving average of $0.92 and a 200 day simple moving average of $1.02.

Hedge Funds Weigh In On Cytosorbents

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sargent Investment Group LLC raised its stake in Cytosorbents by 13.4% during the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after purchasing an additional 192,747 shares during the period. Atomi Financial Group Inc. purchased a new position in shares of Cytosorbents during the third quarter valued at $51,000. Finally, Geode Capital Management LLC raised its position in Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after buying an additional 32,415 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.